【drug-news】【资讯翻译】Regeneron公司将Eylea推向日本市场
发布于 2012-09-30 · 浏览 1827 · IP 北京北京
这个帖子发布于 12 年零 227 天前，其中的信息可能已发生改变或有所发展。
http://www.fiercepharma.com/story/regeneron-keeps-keeping-eylea/2012-09-28
认领翻译的战友请跟帖注明“认领本文翻译，48小时内未完成，请其他战友认领！”
请根据自己专业背景选择认领，如使用翻译软件翻译，被发现者扣分1-2分
请根据自己的专业背景选择相应的资讯认领，经常认领而不能及时提供优质稿件者将被列入黑名单，取消认领资格，请大家注意！
新近参与本次活动的会员请查看：【公告】动态版重启资讯翻译计划：我为人人，人人为我，共同提高
寻找最近的翻译贴请查看：http://search.dxy.cn/?words=%E8%B5%84%E8%AE%AF%E7%BF%BB%E8%AF%91&bid=116&t=1&c=1&age=7&bid=116&limit=30&o=1
翻译时请参照版规 【版务】科技动态版版规及加分细则（ 2014-02-21 更新）
希望参与动态版其他活动的会员请查看版面右边栏的置顶部分
Regeneron Pharmaceuticals' ($REGN) rollout of its highly successful eye treatment, Eylea, continues unabated.
The company announced today that Japanese regulators have approved the treatment for wet age-related macular degeneration (wet AMD) there. That comes a week after it got approval in the European Union for wet AMD. The approval also comes a week after the U.S. approved it for another use, to treat the thickening of the macula of the eye, Reuters points out. The U.S. gave Eylea wet AMD approval in November 2011.
The company says it estimates that there are about 700,000 patients in Japan who could be eligible to be treated with the drug, which can restore some sight in patients. Japan is seen as a promising market for drugmakers of late since regulatory reforms have speeded up new drug launches in a market notoriously slow at adopting treatments already in use elsewhere. The government's pricing policies have eased as well and the island nation's growing aging population is strengthening demand for drugs.
In fact, it was several weeks ago that Novartis ($NVS), whose blockbuster eye drug Lucentis is Eylea's main competitor, said it has data supporting a new indication for the drug and will take that with an application to Japan. The company said that new data found that an average of three Lucentis (ranibizumab) injections improved visual acuity in patients with myopic choroidal neovascularization (CNV). Novartis sells Lucentis outside the U.S. while Roche ($RHHBY) owns the drug there, where Eylea has been stealing away market share.
Lucentis and Eylea both have been shown to restore some sight to patients with AMD, a disease that can lead to blindness. Eylea, however, comes with a lower cost, and has been found to require fewer treatments--at least in the first year of use.
The drug has been so successful for Regeneron that in July, the company for the third time boosted its forecast of sales for the sight-restoring drug. It projected full-year U.S. Eylea sales will tally $700 million to $750 million. That is up 50% from the $500 million to $550 million projected just three months earlier, which was nearly double an earlier projection.
认领翻译的战友请跟帖注明“认领本文翻译，48小时内未完成，请其他战友认领！”
请根据自己专业背景选择认领，如使用翻译软件翻译，被发现者扣分1-2分
请根据自己的专业背景选择相应的资讯认领，经常认领而不能及时提供优质稿件者将被列入黑名单，取消认领资格，请大家注意！
新近参与本次活动的会员请查看：【公告】动态版重启资讯翻译计划：我为人人，人人为我，共同提高
寻找最近的翻译贴请查看：http://search.dxy.cn/?words=%E8%B5%84%E8%AE%AF%E7%BF%BB%E8%AF%91&bid=116&t=1&c=1&age=7&bid=116&limit=30&o=1
翻译时请参照版规 【版务】科技动态版版规及加分细则（ 2014-02-21 更新）
希望参与动态版其他活动的会员请查看版面右边栏的置顶部分
Regeneron Pharmaceuticals' ($REGN) rollout of its highly successful eye treatment, Eylea, continues unabated.
The company announced today that Japanese regulators have approved the treatment for wet age-related macular degeneration (wet AMD) there. That comes a week after it got approval in the European Union for wet AMD. The approval also comes a week after the U.S. approved it for another use, to treat the thickening of the macula of the eye, Reuters points out. The U.S. gave Eylea wet AMD approval in November 2011.
The company says it estimates that there are about 700,000 patients in Japan who could be eligible to be treated with the drug, which can restore some sight in patients. Japan is seen as a promising market for drugmakers of late since regulatory reforms have speeded up new drug launches in a market notoriously slow at adopting treatments already in use elsewhere. The government's pricing policies have eased as well and the island nation's growing aging population is strengthening demand for drugs.
In fact, it was several weeks ago that Novartis ($NVS), whose blockbuster eye drug Lucentis is Eylea's main competitor, said it has data supporting a new indication for the drug and will take that with an application to Japan. The company said that new data found that an average of three Lucentis (ranibizumab) injections improved visual acuity in patients with myopic choroidal neovascularization (CNV). Novartis sells Lucentis outside the U.S. while Roche ($RHHBY) owns the drug there, where Eylea has been stealing away market share.
Lucentis and Eylea both have been shown to restore some sight to patients with AMD, a disease that can lead to blindness. Eylea, however, comes with a lower cost, and has been found to require fewer treatments--at least in the first year of use.
The drug has been so successful for Regeneron that in July, the company for the third time boosted its forecast of sales for the sight-restoring drug. It projected full-year U.S. Eylea sales will tally $700 million to $750 million. That is up 50% from the $500 million to $550 million projected just three months earlier, which was nearly double an earlier projection.
最后编辑于 2012-10-01 · 浏览 1827
3 收藏点赞
